Skip to main content

Kiniksa Pharmaceuticals International, plc

KNSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001730430

In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Kiniksa Pharmaceuticals International, plc changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of KNSA: Q3 2024 compared with Q4 2024
MeasureQ3 2024Of which not filed for Q4 2024Q4 2024Change
Holders1761160−15
Shares39.7M43239.1M−577.4K (−1.5%)
Value$991.2M$10.8K$773.1M−$218.1M (−22.0%)

1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (19)

Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to KNSA in Q4 2024
InstitutionSharesValue% of portfolio
Raymond James Financial Inc199,953$3.96M0.00%
Squarepoint Ops LLC26,808$530.3K0.00%
Intech Investment Management LLC23,002$455.0K0.00%
SG Americas Securities, LLC17,970$355.0K0.00%
State of Wyoming14,806$292.9K0.04%
Federation des caisses Desjardins du Quebec14,006$276.7K0.00%
Y-Intercept (Hong Kong) Ltd13,050$258.1K0.02%
Balyasny Asset Management LLC12,921$255.6K0.00%
Bellevue Group AG8,100$160.2K0.00%
KLP Kapitalforvaltning AS8,000$158.2K0.00%
Police & Firemen's Retirement System of New Jersey7,526$148.9K0.00%
Lazard Asset Management LLC3,098$61.0K0.00%
GF Fund Management Co. Ltd.873$17.3K0.00%
Smartleaf Asset Management LLC214$4.19K0.00%
SBI Securities Co., Ltd.110$2.18K0.00%
Van Hulzen Asset Management, LLC50$9890.00%
Cassady Schiller Wealth Management, LLC37$7320.00%
IFP Advisors, Inc22$4350.00%
EverSource Wealth Advisors, LLC13$2570.00%

Sold out (34)

Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q3 2024 and filed for Q4 2024 without it.

Not filed for Q4 2024 yet (1)

Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding KNSA in Q3 2024 that haven't filed for Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Carmichael Hill & Associates, Inc.432$10.8K